Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Little Green Pharma Ltd. ( (AU:LGP) ) has provided an announcement.
Little Green Pharma Ltd. reported the outcomes of its 22 April 2026 General Meeting, where shareholders voted on several resolutions relating to director termination benefits. Resolutions granting termination benefits to executive directors Angus Caithness and Fleta Solomon, as well as to a non-executive director, were all passed by strong majorities on a poll.
The company confirmed that the key Scheme Consideration Resolution, which concerns the issue of consideration securities, has been postponed to 22 May 2026. This deferral means a crucial decision affecting the company’s capital structure and potential corporate transactions remains pending, leaving stakeholders awaiting further clarity on LGP’s strategic direction.
The most recent analyst rating on (AU:LGP) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Little Green Pharma Ltd. stock, see the AU:LGP Stock Forecast page.
More about Little Green Pharma Ltd.
Little Green Pharma Ltd. is an ASX-listed pharmaceutical company focused on medicinal cannabis products. It operates in the medical cannabis sector, supplying plant-based therapeutics to patients and healthcare markets, with its activities overseen by a board including executive and non-executive directors.
Average Trading Volume: 137,789
Technical Sentiment Signal: Sell
Current Market Cap: A$29.06M
For detailed information about LGP stock, go to TipRanks’ Stock Analysis page.